Pharmacokinetic evaluation of fluconazole in critically ill patients

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 11, 2011, Pages 1431-1440

  Sinnollareddy, Mahipal ^a,b   Peake, Sandra L ^a   Roberts, Michael S ^b   Playford, E Geoffrey ^c,d   Lipman, Jeffrey ^d,e   Roberts, Jason A ^b,d,e  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Critically ill; Dosing; Fluconazole; Pharmacodynamics; Renal replacement therapy

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; ANIDULAFUNGIN; FLUCONAZOLE;

AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; BURN PATIENT; CANDIDA; CANDIDEMIA; CANDIDIASIS; CRITICAL ILLNESS; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EVALUATION; HAIR LOSS; HUMAN; INTENSIVE CARE UNIT; LOADING DRUG DOSE; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME;

ANTIFUNGAL AGENTS; CANDIDIASIS; CANDIDIASIS, INVASIVE; CRITICAL ILLNESS; DRUG EVALUATION; FLUCONAZOLE; HUMANS;

CANDIDA;

EID: 80054754492     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.615309     Document Type: Review

References (85)

1. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993;24:10-27 (Pubitemid 23042127)
2. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410 (Pubitemid 43240191)
3. Thaler F, Bernard B, Tod M, et al. Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob Agents Chemother 1995;39:1154-6
4. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis 2009;48:503-35
5. Eggimann P, Garbino J, Pittet D. Epidemiology of candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702 (Pubitemid 37345347)
6. Zilberberg MD, Kollef MH, Arnold H, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010;10:150-4
7. Labelle AJ, Micek ST, Roubinian N, et al. Treatment-related risk factors for hospital mortality in candida bloodstream infections. Crit Care Med 2008;36:2967-72
8. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-17 (Pubitemid 29484744)
9. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9
10. Holley A, Dulhunty J, Blot S, et al. Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents 2009;33:554,e1-7
11. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254-9 (Pubitemid 32830323)
12. Pereira GH, Muller PR, Szeszs MW, et al. Five-year evaluation of bloodstream yeast infections in a tertiary hospital: the predominance of non-C. albicans candida species. Med Mycol 2010;48:839-42
13. Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006;34:857-63
14. Klingspor L, Tornqvist E, Johansson A, et al. Prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004;36:52-5 (Pubitemid 38219772)
15. Trick WE, Fridkin SK, Edwards JR, et al. National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the united states during 1989-1999. Clin Infect Dis 2002;35:627-30
16. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in swisstertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004;38:311-20 (Pubitemid 38200105)
17. Playford EG, Nimmo GR, Tilse M, et al. Increasing incidence of candidaemia: long-term epidemiological trends, queensland, australia, 1999-2008. J Hosp Infect 2010;76:46-51
18. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63 (Pubitemid 46167771)
19. Playford EG, Marriott D, Nguyen Q, et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans candida spp. Crit Care Med 2008;36:2034-9
20. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Semi-national surveillance of fungaemia in denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect 2008;14:487-94 (Pubitemid 351513938)
21. Arendrup MC, Fuursted K, Gahrn-Hansen B, et al. Seminational surveillance of fungemia in denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 2005;43:4434-40 (Pubitemid 41298224)
22. Pfaller MA, Diekema DJ, Steele-Moore L, et al. Twelve years of fluconazole in clinical practice: global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of candida. Clin Microbiol Infect 2004;10:11-23 (Pubitemid 38386593)
23. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43:S3-14
24. Chow JK, Golan Y, Ruthazer R, et al. Factors associated with candidemia caused by non-albicans candida species versus candida albicans in the intensive care unit. Clin Infect Dis 2008;46:1206-13 (Pubitemid 351589904)
25. Chow JK, Golan Y, Ruthazer R, et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008;36:1993-8
26. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010;54:3149-54
27. Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of candida glabrata: an assessment from the ARTEMIS DISK global antifungal surveillance program. Diagn Microbiol Infect Dis 2010;67:162-71
28. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007;45:1735-45 (Pubitemid 46933900)
29. Rajagopalan P, Pelz RK, Lipsett PA, et al. Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit. Pharmacotherapy 2003;23:592-602 (Pubitemid 36539040)
30. Zhou W, Nightingale CH, Davis GA, et al. Absolute bioavailability of fluconazole suspension in intensive care unit patients. J Infect Dis Pharmacother 2001;5:27-35 (Pubitemid 33098061)
31. Rosemurgy AS, Markowsky S, Goode SE, et al. Bioavailability of fluconazole in surgical intensive care unit patients: a study comparing routes of administration. J Trauma Inj Infect Crit Care 1995;39:445-7
32. Nicolau DP, Crowe H, Nightingale CH, et al. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J Antimicrob Chemother 1995;36:395-401
33. Nicolau DP, Crowe H, Nightingale CH, et al. Effect of continuous arteriovenous hemodiafiltration on the pharmacokinetics of fluconazole. Pharmacotherapy 1994;14:502-5 (Pubitemid 24238185)
34. Buijk SLCE, Gyssens IC, Mouton JW, et al. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med 2001;27:115-21 (Pubitemid 32208977)
35. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. the national institute of allergy and infectious diseases (NIAID) mycoses study group. Clin Infect Dis 2000;30:19-24
36. Wong SF, Leung MP, Chan MY. Pharmacokinetics of fluconazole in children requiring peritoneal dialysis. Clin Ther 1997;19:1039-47 (Pubitemid 27508938)
37. Debruyne D, Ryckelynck JP. Fluconazole serum, urine, and dialysate levels in CAPD patients. Perit Dial Int 1992;12:328-9
38. Bergner R, Hoffmann M, Riedel KD, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant 2006;21:1019-23
39. Kishino S, Koshinami Y, Hosoi T, et al. Effective fluconazole therapy for liver transplant recipients during continuous hemodiafiltration. Ther Drug Monit 2001;23:4-8 (Pubitemid 32105958)
40. Muhl E, Martens T, Iven H, et al. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 2000;56:671-8 (Pubitemid 32204487)
41. Scholz J, Schulz M, Steinfath M, et al. Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient. J Mol Med 1995;73:145-7
42. Valtonen M, Tiula E, Neuvonen PJ. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother 1997;40:695-700 (Pubitemid 27504001)
43. Yagasaki K, Gando S, Matsuda N, et al. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 2003;29:1844-8 (Pubitemid 37373838)
44. Wolter K, Marggraf G, Dermoumi H, et al. Elimination of fluconazole during continuous veno-venous haemodialysis (CVVHD) in a single patient. Eur J Clin Pharmacol 1994;47:291-2 (Pubitemid 24330673)
45. Blanchet B, Jullien V, Vinsonneau C, et al. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008;47:635-54
46. Boucher BA, King SR, Wandschneider HL, et al. Fluconazole pharmacokinetics in burn patients. Antimicrob Agents Chemother 1998;42:930-3 (Pubitemid 28216382)
47. Honiden S, McArdle JR. Obesity in the intensive care unit. Clin Chest Med 2009;30:581-99
48. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007;27:1081-91
49. Cohen LG, DiBiasio A, Lisco SJ, et al. Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy 1997;17:1023-6 (Pubitemid 27415107)
50. Garey KW, Pai MP, Suda KJ, et al. Inadequacy of fluconazole dosing in patients with candidemia based on infectious diseases society of america (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007;16:919-27 (Pubitemid 47322590)
51. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999;43:2116-20 (Pubitemid 29421186)
52. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998;42:1105-9 (Pubitemid 28227905)
53. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006;20:679-97 (Pubitemid 44375115)
54. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003;47:1179-86 (Pubitemid 36368572)
55. Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005;49:3171-7 (Pubitemid 41060556)
56. Rodriguez-Tudela JL, Almirante B, Rodriguez-Pardo D, et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007;51:3599-604 (Pubitemid 47519349)
57. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007;51:35-9 (Pubitemid 46047684)
58. Baddley JW, Patel M, Bhavnani SM, et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008;52:3022-8
59. Shin JH, Kee SJ, Shin MG, et al. Biofilm production by isolates of candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002;40:1244-8 (Pubitemid 34279883)
60. Lewis RE, Kontoyiannis DP, Darouiche RO, et al. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of candida catheter-related bloodstream infection. Antimicrob Agents Chemother 2002;46:3499-505 (Pubitemid 35192917)
61. Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002;46:1773-80 (Pubitemid 34535196)
62. Martinez LR, Fries BC. Fungal biofilms: relevance in the setting of human disease. Curr Fungal Infect Rep 2010;4:266-75
63. Gafter-Gvili A, Vidal L, Goldberg E, et al. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 2008;83:1011-21
64. Playford EG, Lipman J, Sorrell TC. Management of invasive candidiasis in the intensive care unit. Drugs 2010;70:823-39
65. Playford EG, Webster AC, Sorrell TC, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006;57:628-38
66. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. candidemia study group and the national institute. N Engl J Med 1994;331:1325-30 (Pubitemid 24347001)
67. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997;16:337-45 (Pubitemid 27271820)
68. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-72 (Pubitemid 26367478)
69. Abele-Horn M, Kopp A, Sternberg U, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic candida infections in intensive care patients. Infection 1996;24:426-32 (Pubitemid 27023090)
70. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-8 (Pubitemid 36629929)
71. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82 (Pubitemid 46919773)
72. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-8 (Pubitemid 36629929)
73. Diaz M, Negroni R, Montero-Gei F, et al. A pan-american 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. pan-american study group. Clin Infect Dis 1992;14:S68-76
74. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. california collaborative treatment group. N Engl J Med 1991;324:580-4
75. Voss A, de Pauw BE. High-dose fluconazole therapy in patients with severe fungal infections. Eur J Clin Microbiol Infect Dis 1999;18:165-74 (Pubitemid 29527949)
76. Garbino J, Lew DP, Romand JA, et al. Prevention of severe candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002;28:1708-17 (Pubitemid 35435471)
77. Crerar-Gilbert A, Boots R, Fraenkel D, et al. Survival following fulminant hepatic failure from fluconazole induced hepatitis. Anaesth Intensive Care 1999;27:650-2 (Pubitemid 30021088)
78. Albert SG, DeLeon MJ, Silverberg AB. Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. Crit Care Med 2001;29:668-70 (Pubitemid 32225315)
79. Michaelis G, Zeiler D, Biscoping J, et al. Function of the adrenal cortex during therapy with fluconazole in intensive care patients. Mycoses 1993;36:117-23 (Pubitemid 23181649)
80. Magill SS, Puthanakit T, Swoboda SM, et al. Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients. Antimicrob Agents Chemother 2004;48:2471-6 (Pubitemid 38823412)
81. Anaissie EJ, Kontoyiannis DP, Huls C, et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995;172:599-602
82. Gussenhoven MJ, Haak A, Peereboom-Wynia JD, et al. Stevens-johnson syndrome after fluconazole. Lancet 1991;338:120-1
83. Thiyanaratnam J, Cohen PR, Powell S. Fluconazole-associated stevens-johnson syndrome. J Drugs Dermatol 2010;9:1272-5
84. Udy AA, Putt MT, Shanmugathasan S, et al. Augmented renal clearance in the intensive care unit: an illustrative case series. Int J Antimicrob Agents 2010;35:606-8
85. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010;49:1-16